COMMUNIQUÉS West-GlobeNewswire
-
Zevra Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
18/11/2026 -
Surgery Partners, Inc. Announces Increased Consent Fee in Consent Solicitation Relating to Surgery Center Holdings, Inc.’s 7.250% Senior Notes due 2032
18/11/2026 -
Immuneering Presents Additional Data Demonstrating Atebimetinib’s Broad Potential as a Backbone for Combination Therapy in Pancreatic Cancer
18/11/2026 -
Immuneering Presents Data That Supports Expanding the Clinical Evaluation of Atebimetinib to Anaplastic Thyroid Cancer
18/11/2026 -
Optimi Health Outlines 2027 Plans for OPTI-101 Phase 2b in Major Depressive Disorder and OPTI-201 Phase 3 in PTSD; Announces Shares-for-Debt Settlement
18/11/2026 -
Conavi Medical Announces Five-Year Extension of Credit Facilities with Japan Lifeline
18/11/2026 -
NervGen Appoints Neuroscience Drug Development Leader Sam Jackson, MD, MBA, as Chief Medical Officer
18/11/2026 -
Aquestive Therapeutics to Present at the Piper Sandler 38th Annual Healthcare Conference
18/11/2026 -
Visara Announces First Patient Dosed in ASCEND Phase 2b Trial of VIS-101 in Wet AMD
18/11/2026 -
Can-Fite Pivotal Phase III Psoriasis Study Under an FDA- and EMA-agreed protocol: All Patients Completed Dosing and Interim Analysis Expected Q1 2027
18/11/2026 -
Virbac to Participate in the Jefferies Global Healthcare Conference in London
18/11/2026 -
UREVO Announces Black Friday Sale 2026 with Its Biggest Discounts of the Year
18/11/2026 -
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Increased Dose of 15 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
18/11/2026 -
Adaptive Biotechnologies Highlights clonoSEQ’s Central Role in Advancing MRD-Guided Care Across Hematology at ASH 2026
18/11/2026 -
Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium
18/11/2026 -
Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case
18/11/2026 -
Nyxoah Obtient une Décision par Défaut contre Inspire Medical Systems dans une Procédure devant l’Unified Patent Court
18/11/2026 -
Zealand Pharma announces initiation of the Phase 2 ZYNERGY trial of petrelintide co-administered with enicepatide in people with obesity or overweight
18/11/2026 -
Novo Nordisk Foundation commits US$60 million to strengthen CARB-X efforts against antimicrobial resistance
18/11/2026
Pages